

## New functionalities in Orphanet for orphan drugs, R&D and marketing authorisations to better serve the rare disease community

Hivert V., Martin N., Hanauer M., Aymé S. & the Orphanet consortium\* ; INSERM, SC11 - Orphanet, Paris, France.

The Orphanet "Orphan Drugs" database includes a list of all substances that have been granted an orphan designation for a disease(s) considered as rare in Europe, whether further developed to become drugs with marketing authorisation (MA) or not. The Orphanet database also includes drugs without an orphan designation as long as they have been granted a MA with a specific indication for a rare disease. The Orphanet "Clinical trials" database includes on-going trials for rare diseases in European countries.

### Key figures:

- 883 ongoing clinical trials for 345 rare diseases
- 994 orphan designations for 425 rare diseases
- 303 rare diseases with at least one product on the market
- 195 rare diseases with at least one orphan product on the market
- 58 European orphan drugs for 90 rare diseases

## A recalibrated search engine to render data more accessible

### The Orphan Drugs tab

**4 new sub-tabs:**

- List of orphan designations
- List of orphan drugs with marketing authorisation
- List of substances
- List of drugs

### The Clinical Trials tab

**Search by a wide range of criteria**

## Information provided by Orphanet on orphan drugs and clinical trials

### Information on orphan products by substance or tradename

### Information on a clinical trial

## Orphanet Report Series

A quarterly report listing orphan drugs on the European market with or without prior orphan designation. Freely available on [www.orpha.net](http://www.orpha.net)

For further information, please visit [www.orpha.net](http://www.orpha.net)